Request for Medicaid and CHIP Payment and Access Commission (MACPAC) Nominations, 225 [2021-27494]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 2 / Tuesday, January 4, 2022 / Notices
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board,
20th Street and Constitution Avenue
NW, Washington, DC 20551–0001, not
later than January 18, 2022.
A. Federal Reserve Bank of New York
(Ivan Hurwitz, Senior Vice President) 33
Liberty Street, New York, New York
10045–0001. Comments can also be sent
electronically to
Comments.applications@ny.frb.org:
1. AIB Group, p.l.c., Dublin, Ireland;
to retain GANMAC Holdings (BVI)
Limited, and thereby indirectly retain
Goodbody Securities, Inc., both of
Dublin, Ireland, and engage in securities
brokerage activities pursuant to section
225.28(b)(7)(i) of the Board’s Regulation
Y.
Board of Governors of the Federal Reserve
System, December 28, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–28462 Filed 1–3–22; 8:45 am]
GOVERNMENT ACCOUNTABILITY
OFFICE
Request for Medicaid and CHIP
Payment and Access Commission
(MACPAC) Nominations
U.S. Government
Accountability Office (GAO).
ACTION: Request for letters of
nomination and resumes.
AGENCY:
The Children’s Health
Insurance Program Reauthorization Act
of 2009 (CHIPRA) established MACPAC
to review Medicaid and CHIP access
and payment policies and to advise
Congress on issues affecting Medicaid
and CHIP. CHIPRA gave the Comptroller
General of the United States
responsibility for appointing MACPAC’s
SUMMARY:
tkelley on DSK125TN23PROD with NOTICE
Submit letters of
nomination and resumes to
MACPACappointments@gao.gov.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Susan Anthony at (312) 220–7666 or
anthonys@gao.gov if you do not receive
an acknowledgment or need additional
information. For general information,
contact GAO’s Office of Public Affairs,
(202) 512–4800.
(Authority: Pub. L. 111–3, sec. 506; 42 U.S.C.
1396.)
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2021–27494 Filed 1–3–22; 8:45 am]
BILLING CODE 1610–02–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0506]
William Kulakevich: Final Debarment
Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) debarring
William Kulakevich for a period of 5
years from importing or offering for
import any drug into the United States.
FDA bases this order on a finding that
Mr. Kulakevich was convicted of one
felony count under Federal law for
conspiracy to commit offenses against
the United States. The factual basis
supporting Mr. Kulakevich’s conviction,
as described below, is conduct relating
to the importation into the United States
of a drug or controlled substance. Mr.
Kulakevich was given notice of the
proposed debarment and was given an
opportunity to request a hearing to show
why he should not be debarred. As of
September 16, 2021 (30 days after
receipt of the notice), Mr. Kulakevich
had not responded. Mr. Kulakevich’s
SUMMARY:
BILLING CODE P
VerDate Sep<11>2014
members. GAO is now accepting
nominations for MACPAC appointments
that will be effective May 2022.
Nominations should be sent to the email
address listed below. Acknowledgement
of receipt will be provided within a
week of submission.
DATES: Letters of nomination and
resumes should be submitted no later
than January 27, 2022, to ensure
adequate opportunity for review and
consideration of nominees prior to
appointment.
18:43 Jan 03, 2022
Jkt 256001
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
225
failure to respond and request a hearing
constitutes a waiver of his right to a
hearing concerning this matter.
DATES: This order is applicable January
4, 2022.
ADDRESSES: Submit applications for
termination of debarment to the Dockets
Management Staff, Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, 240–402–
7500, or at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, Division of Enforcement
(ELEM–4029), Office of Strategic
Planning and Operational Policy, Office
of Regulatory Affairs, Food and Drug
Administration, 12420 Parklawn Dr.,
Rockville, MD 20857, 240–402–8743, or
at debarments@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(D) of the FD&C Act
(21 U.S.C. 335a(b)(1)(D)) permits
debarment of an individual from
importing or offering for import any
drug into the United States if FDA finds,
as required by section 306(b)(3)(C) of the
FD&C Act, that the individual has been
convicted of a felony for conduct
relating to the importation into the
United States of any drug or controlled
substance. On July 23, 2019, Mr.
Kulakevich was convicted, as defined in
section 306(l)(1) of FD&C Act, in the
U.S. District Court for the Western
District of Pennsylvania, when the court
entered judgment against him for the
offense of conspiracy to commit offenses
against the United States, in violation of
18 U.S.C. 2 and 371.
FDA’s finding that debarment is
appropriate is based on the felony
conviction referenced herein. The
factual basis for this conviction is as
follows: As contained in the indictment
in Mr. Kulakevich’s case, filed August
22, 2017, to which he plead guilty, from
on or about April 2015, and continuing
until May 2017, Mr. Kulakevich was the
owner and a co-operator of a website,
www.etizy.com, through which he sold
and distributed a drug known as
etizolam to consumers throughout the
United States. Etizolam is a drug known
as thienodiazepine, which is chemically
similar to benzodiazepines and carries
risks of dependency, toxicity, and the
possibility of fatal overdose. Etizolam is
not FDA-approved in the United States.
Mr. Kulakevich and his co-conspirator
illegally bought etizolam from an
overseas supplier in India, after which
he arranged to have it smuggled into the
United States through the use of
multiple post office boxes controlled by
him and his coconspirator. To avoid
Federal regulators, Mr. Kulakevich used
E:\FR\FM\04JAN1.SGM
04JAN1
]]>Agencies
[Federal Register Volume 87, Number 2 (Tuesday, January 4, 2022)]
[Notices]
[Page 225]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27494]
=======================================================================
-----------------------------------------------------------------------
GOVERNMENT ACCOUNTABILITY OFFICE
Request for Medicaid and CHIP Payment and Access Commission
(MACPAC) Nominations
AGENCY: U.S. Government Accountability Office (GAO).
ACTION: Request for letters of nomination and resumes.
-----------------------------------------------------------------------
SUMMARY: The Children's Health Insurance Program Reauthorization Act of
2009 (CHIPRA) established MACPAC to review Medicaid and CHIP access and
payment policies and to advise Congress on issues affecting Medicaid
and CHIP. CHIPRA gave the Comptroller General of the United States
responsibility for appointing MACPAC's members. GAO is now accepting
nominations for MACPAC appointments that will be effective May 2022.
Nominations should be sent to the email address listed below.
Acknowledgement of receipt will be provided within a week of
submission.
DATES: Letters of nomination and resumes should be submitted no later
than January 27, 2022, to ensure adequate opportunity for review and
consideration of nominees prior to appointment.
ADDRESSES: Submit letters of nomination and resumes to
[email protected].
FOR FURTHER INFORMATION CONTACT: Susan Anthony at (312) 220-7666 or
[email protected] if you do not receive an acknowledgment or need
additional information. For general information, contact GAO's Office
of Public Affairs, (202) 512-4800.
(Authority: Pub. L. 111-3, sec. 506; 42 U.S.C. 1396.)
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2021-27494 Filed 1-3-22; 8:45 am]
BILLING CODE 1610-02-P
